SNTI vs. GIA, INAB, ALGS, OKYO, NKGN, QNCX, ACHL, CYTH, SRZN, and BCLI
Should you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include GigCapital5 (GIA), IN8bio (INAB), Aligos Therapeutics (ALGS), OKYO Pharma (OKYO), NKGen Biotech (NKGN), Quince Therapeutics (QNCX), Achilles Therapeutics (ACHL), Cyclo Therapeutics (CYTH), Surrozen (SRZN), and Brainstorm Cell Therapeutics (BCLI).
Senti Biosciences (NASDAQ:SNTI) and GigCapital5 (NYSE:GIA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.
In the previous week, Senti Biosciences' average media sentiment score of 0.00 equaled GigCapital5'saverage media sentiment score.
Senti Biosciences received 3 more outperform votes than GigCapital5 when rated by MarketBeat users.
GigCapital5 has lower revenue, but higher earnings than Senti Biosciences.
Senti Biosciences has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, GigCapital5 has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500.
GigCapital5 has a net margin of 0.00% compared to Senti Biosciences' net margin of -2,692.82%. GigCapital5's return on equity of 0.00% beat Senti Biosciences' return on equity.
Senti Biosciences presently has a consensus price target of $6.00, indicating a potential upside of 2,038.28%. Given Senti Biosciences' higher probable upside, analysts clearly believe Senti Biosciences is more favorable than GigCapital5.
25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 27.3% of GigCapital5 shares are held by institutional investors. 15.9% of Senti Biosciences shares are held by company insiders. Comparatively, 75.4% of GigCapital5 shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
GigCapital5 beats Senti Biosciences on 6 of the 11 factors compared between the two stocks.
Get Senti Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Senti Biosciences Competitors List
Related Companies and Tools
